Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 18/20 | 0.70 |
| ▸ | FLT3 | P36888 | 2/20 | 0.64 |
| ▸ | KIT | P10721 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 6/20 | 0.64 |
| ▸ | ITK | Q08881 | 3/20 | 0.63 |
| ▸ | LCK | P06239 | 2/20 | 0.63 |
| ▸ | TEC | P42680 | 3/20 | 0.62 |
| ▸ | BMX | P51813 | 3/20 | 0.62 |
| ▸ | TXK | P42681 | 2/20 | 0.62 |
| ▸ | LYN | P07948 | 2/20 | 0.62 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.62 |
| ▸ | LATS1 | O95835 | 1/20 | 0.62 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.62 |
| ▸ | FYN | P06241 | 1/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27949504 | 1.00 | BTK (0.70) | BTKFLT3KITEGFRITK | |
| SCHEMBL17626682 | 0.92 | EGFR (0.75) | BTKFLT3KITEGFRITK | |
| SCHEMBL17626684 | 0.92 | EGFR (0.75) | BTKFLT3KITEGFRITK | |
| SCHEMBL24196860 | 0.91 | BTK (0.60) | BTKFLT3KITEGFRITK | |
| SCHEMBL29671300 | 0.91 | BTK (0.81) | BTKFLT3KITEGFRITK | |
| SCHEMBL1628863 | 0.91 | BTK (0.81) | BTKFLT3KITEGFRITK | |
| SCHEMBL12808088 | 0.91 | BTK (0.81) | BTKFLT3KITEGFRITK | |
| SCHEMBL30324920 | 0.91 | BTK (0.81) | BTKFLT3KITEGFRITK | |
| SCHEMBL15641034 | 0.91 | BTK (0.81) | BTKFLT3KITEGFRITK | |
| SCHEMBL30415972 | 0.91 | BTK (0.58) | BTKFLT3KITEGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376438-B2 | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | BMX, BLK, TEC | BTK 5/4885FLT3 62/4885KIT 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.